<DOC>
	<DOCNO>NCT00787488</DOCNO>
	<brief_summary>This pilot study aim test feasibility safety administer combination chemotherapy paclitaxel ( intravenously intraperitoneally ) cisplatin ( intraperitoneally ) plus whole abdominal hyperthermia every 3 week treatment optimally debulked , advance recurrent ovarian , primary peritoneal , fallopian tube cancer patient .</brief_summary>
	<brief_title>Pilot Study IV IP Chemotherapy Plus Abdominal Hyperthermia Ovarian Ca</brief_title>
	<detailed_description>Day 1 21 day Cycle : Paclitaxel 175 mg/m2 IV ( infused 3 hour ) Day 1 2 Cycle Adequate IV hydration normal saline ( 1000 ml recommend ) follow intraperitoneal infusion 500 ml normal saline IP port . Cisplatin 75 mg/m2 reconstitute 500 ml NS warm 37 degree Celsius infuse IP ( 30 minute infusion ) follow immediately whole abdominal hyperthermia Abdominal hyperthermia deliver use BSD 2000 ellipse system target temperatures 40-42 degree Celsius monitor via rectally vaginally continue great 60 minute maximal 30 minute warm-up phase . Total duration hyperthermia great 90 minute . Day 8 : Paclitaxel 60 mg/m2 IP . Paclitaxel dilute filter initially 1000 ml normal saline D5W warm 37 degree Celsius . For IP administration , patient must receive additional 1000 ml normal saline degree Celsius peritoneal cavity . Cycles repeat every 3 week x 6 cycle . Patients follow disease progression/recurrence death .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<criteria>Histologically diagnose Stage III Stage IV advance , persistent , recurrent epithelial ovarian , primary peritoneal , fallopian tube cancer Optimal debulking ( &lt; 1cm residual disease ) disease within 6 week start study Patients must receive 2 prior chemotherapy regimen least 4 week since prior chemotherapy GOG performance status 0 , 1 , 2 Patients must normal organ marrow function define : absolute neutrophil count &gt; 1,500/mcL platelet &gt; 100,000/mcL total bilirubin creatinine &lt; 1.5 X institutional upper limit normal ( ULN ) AST ( SGOT ) /ALT ( SGPT ) &lt; 3 X institutional ULN Patients biochemical recurrence evidence measurable disease Patients suboptimal ( &gt; 1 cm ) residual disease Patients chemotherapy within 4 week prior Receiving investigational agent Known brain metastasis Epithelial ovarian carcinoma low malignant potential ( borderline carcinoma ) Uncontrolled intercurrent illness Prior radiation therapy History invasive preinvasive malignancy ( except nonmelanoma skin cancer ) within past 5 year</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Ovarian</keyword>
	<keyword>debulked</keyword>
	<keyword>recurrent</keyword>
	<keyword>Stage III</keyword>
	<keyword>Stage IV</keyword>
</DOC>